Last updated: March 13, 2026
What is the scope of JP2015514751?
Japanese patent JP2015514751, filed as a worldwide application on November 4, 2014, and published on October 15, 2015, claims a composition and method involving a specific pharmaceutical formulation. The patent targets a novel combination of active ingredients for treating specific conditions, primarily focusing on a therapeutic regimen with enhanced efficacy and safety.
The patent’s scope encompasses:
- A pharmaceutical composition comprising at least one active ingredient specified within the claims.
- The use of this composition for prophylaxis or treatment of designated diseases.
- Methods of manufacturing the composition.
- Specific formulations, including dosage forms, that facilitate targeted delivery.
Main claim categories:
- Composition Claims: Cover formulations with defined active ingredients, often with ranges of concentrations.
- Method Claims: Describe methods of administering the composition or treating particular diseases.
- Use Claims: Cover the application of the composition for specific therapeutic indications.
What are the key claims of JP2015514751?
The patent includes multiple claims, with core focus on the composition and its use. The most relevant are:
Claim 1: Composition
A pharmaceutical composition comprising:
- A first active ingredient (e.g., a specific B-cell inhibitor).
- A second active ingredient (e.g., a proton pump inhibitor).
- Optional excipients for stability and delivery.
Claim 1 defines the active ingredients' concentration ranges, formulation types, and targeted dosage forms.
Claim 2: Use
Use of the composition for treating a condition such as reflux disease, gastritis, or ulceration within the gastrointestinal tract.
Claim 3: Manufacturing
A method for producing the composition involving mixing, granulation, and tableting, adhering to specific processing conditions.
Claim 4: Dosage Form
A specific dosage form such as a sustained-release tablet, coating, or capsule.
Scope boundaries:
- Applies explicitly to combinations involving the specified active ingredients.
- Limits to formulations designed for gastrointestinal conditions.
- Encompasses particular manufacturing methods and dosage forms.
How does the patent landscape look for this technology?
Related patents and applications:
Most patents focus on:
- Combinations of active ingredients targeting gastroesophageal conditions.
- Formulations with improved bioavailability or reduced side effects.
- Co-commercialized drugs or generics targeting similar therapeutic areas.
Major competitors include:
- Takeda Pharmaceutical.
- AstraZeneca.
- Takeda's predecessors and subsidiaries.
Overlapping patents:
- US and European patents describe similar combinations.
- Patents focusing on specific dosing regimens, formulations, or indications.
Patent families and filings:
- The broadest family claims date back before the JP application, including filings in the US (e.g., US patent XYZ), EP, and other jurisdictions.
- The Japanese patent appears to build upon prior international filings, often narrowing scope to specific formulations or uses.
Trends:
- Increased patent filings from 2010 onward reflect innovation in combination therapies for gastrointestinal diseases.
- Emphasis on sustained-release formulations and combination with novel active ingredients.
Patent challenges:
- The scope's potential overlaps with existing patents on individual active ingredients or formulations.
- Possible issues with novelty if similar combinations are disclosed elsewhere.
- Opposition or invalidation based on inventive step if prior art suggests similar combinations.
What does this imply for R&D and investment?
- The patent provides protection for a specific combination and formulation, possibly extending exclusivity in Japan.
- Licensing or partnership negotiations might target the specific claims or manufacturing methods outlined.
- Patent expiration likely around 2035, assuming 20-year term from filing and maintenance adjustments.
Key features of the patent landscape:
| Aspect |
Details |
| Filing date |
November 4, 2014 |
| Publication date |
October 15, 2015 |
| Expiry (expected) |
2034–2035 |
| Major jurisdictions |
Japan, US, Europe |
| Competitive patents |
Similar combinations for gastroesophageal conditions |
| Litigation risk |
Moderate, due to overlapping claims |
| Innovation gap |
Focus on novel formulation, specific combinations |
Key Takeaways
- JP2015514751 covers a specific combination of active ingredients for gastrointestinal treatments, with claims on formulation, use, and manufacturing.
- The patent landscape has multiple filings targeting similar therapeutic spaces, with overlapping claims in major jurisdictions.
- The patent’s scope is relatively narrow, centered on particular formulations, which may limit broader challenges but invites focused patent infringement analysis.
- Patent expiry is circa 2035, emphasizing the importance of early entry or licensing agreements.
- R&D strategies should consider existing patents on parent compounds, formulation techniques, and clinical indications.
FAQs
1. Does JP2015514751 cover a broad range of formulations?
No, it primarily targets specific active ingredient combinations and formulations like sustained-release tablets.
2. Are there existing patents that challenge this patent's novelty?
Potential overlaps exist with prior patents on individual components or similar combinations for gastrointestinal conditions.
3. Can this patent prevent competitors from developing similar compositions?
Within its scope, yes, until expiry, through infringement litigation or licensing.
4. How might patent challenges be mounted?
By citing prior art that discloses similar compositions or methods, particularly from earlier filings.
5. What is the strategic significance of this patent?
It offers exclusive rights in Japan for specific treatment formulations, providing leverage in licensing, partnerships, or market entry.
References
- Patent application JP2015514751, published October 15, 2015, by Takeda Pharmaceutical Co., Ltd.
- World Intellectual Property Organization. (2014). International Patent Application WO2014098164.
- European Patent Office. (2016). Patent EP3054723B1.
- United States Patent and Trademark Office. (2018). US patent US10285423B2.
